Journal of Pain and Symptom Management
Volume 40, Issue 2 , Pages 191-199 , August 2010

Does Recall Period Have an Effect on Cancer Patients' Ratings of the Severity of Multiple Symptoms?

  • Qiuling Shi, MD, PhD, MSc

      Affiliations

    • Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    • Corresponding Author InformationAddress correspondence to: Qiuling Shi, MD, PhD, MSc, Department of Symptom Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1450, Houston, TX 77030, USA.
    • ,
  • Peter C. Trask, PhD, MPH

      Affiliations

    • Global Outcomes Research, Pfizer Inc., New London, Connecticut, USA
    • ,
  • Xin Shelley Wang, MD, MPH

      Affiliations

    • Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Tito R. Mendoza, PhD

      Affiliations

    • Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Winifred A. Apraku, MPH

      Affiliations

    • Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Maggie Malekifar, PTCB

      Affiliations

    • Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Charles S. Cleeland, PhD

      Affiliations

    • Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

,Accepted 4 January 2010.

References 

  1. Cleeland CS. Symptom burden: multiple symptoms and their impact as patient-reported outcomes. J Natl Cancer Inst Monogr. 2007;37:16–21
  2. Wang XS, Fairclough DL, Liao Z, et al. Longitudinal study of the relationship between chemoradiation therapy for non-small-cell lung cancer and patient symptoms. J Clin Oncol. 2006;24:4485–4491
  3. U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Available from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071975.pdfAccessed June 11, 2010
  4. Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer. 2000;89:1634–1646
  5. Kirkova J, Davis MP, Walsh D, et al. Cancer symptom assessment instruments: a systematic review. J Clin Oncol. 2006;24:1459–1473
  6. Gabrilove JL, Perez EA, Tomita DK, Rossi G, Cleeland CS. Assessing symptom burden using the M.D. Anderson symptom inventory in patients with chemotherapy-induced anemia: results of a multicenter, open-label study (SURPASS) of patients treated with darbepoetin-alpha at a dose of 200 microg every 2 weeks. Cancer. 2007;110:1629–1640
  7. Northouse LL, Mood DW, Schafenacker A, et al. Randomized clinical trial of a family intervention for prostate cancer patients and their spouses. Cancer. 2007;110:2809–2818
  8. Gning I, Trask PC, Mendoza TR, et al. Development and initial validation of the thyroid cancer module of the M.D. Anderson Symptom Inventory. Oncology. 2009;76:59–68
  9. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–655
  10. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23:129–138
  11. Cleeland CS, Gonin R, Baez L, Loehrer P, Pandya KJ. Pain and treatment of pain in minority patients with cancer. The Eastern Cooperative Oncology Group Minority Outpatient Pain Study. Ann Intern Med. 1997;127:813–816
  12. Eich E, Reeves JL, Jaeger B, Graff-Radford SB. Memory for pain: relation between past and present pain intensity. Pain. 1985;23:375–380
  13. Harvey AG, Bryant RA. Memory for acute stress disorder symptoms: a two-year prospective study. J Nerv Ment Dis. 2000;188:602–607
  14. Meek PM, Lareau SC, Anderson D. Memory for symptoms in COPD patients: how accurate are their reports?. Eur Respir J. 2001;18:474–481
  15. Miranda H, Gold JE, Gore R, Punnett L. Recall of prior musculoskeletal pain. Scand J Work Environ Health. 2006;32:294–299
  16. Wells JE, Horwood LJ. How accurate is recall of key symptoms of depression? A comparison of recall and longitudinal reports. Psychol Med. 2004;34:1001–1011
  17. Sprangers MA, Schwartz CE. The challenge of response shift for quality-of-life-based clinical oncology research. Ann Oncol. 1999;10:747–749
  18. Schwartz CE, Sprangers MA. Methodological approaches for assessing response shift in longitudinal health-related quality-of-life research. Soc Sci Med. 1999;48:1531–1548
  19. Andrykowski MA, Donovan KA, Jacobsen PB. Magnitude and correlates of response shift in fatigue ratings in women undergoing adjuvant therapy for breast cancer. J Pain Symptom Manage. 2009;37:341–351
  20. Ivanova MO, Ionova TI, Kalyadina SA, et al. Cancer-related symptom assessment in Russia: validation and utility of the Russian M.D. Anderson Symptom Inventory. J Pain Symptom Manage. 2005;30:443–453
  21. Yamagishi A, Morita T, Miyashita M, Kimura F. Symptom prevalence and longitudinal follow-up in cancer outpatients receiving chemotherapy. J Pain Symptom Manage. 2009;37:823–830

 This project was funded by Pfizer, Inc.

PII: S0885-3924(10)00306-4

doi: 10.1016/j.jpainsymman.2009.12.010

Journal of Pain and Symptom Management
Volume 40, Issue 2 , Pages 191-199 , August 2010

Article Tools

* Image Usage & Resolution